Statin use and its potential therapeutic role in esophageal cancer: a systematic review and meta-analysis
Authors Zhou C, Zhong X, Gao P, Wu Z, Shi J, Guo Z, Wang Z, Song Y
Received 8 November 2018
Accepted for publication 30 April 2019
Published 19 June 2019 Volume 2019:11 Pages 5655—5663
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Andrew Yee
Peer reviewer comments 2
Editor who approved publication: Dr Rituraj Purohit
Cen Zhou,* Xi Zhong,* Peng Gao, Zhonghua Wu, Jinxin Shi, Zhexu Guo, Zhenning Wang, Yongxi Song
Department of Surgical Oncology and General Surgery, The First Hospital of China Medical University, Shenyang 110001, People’s Republic of China
*These authors contributed equally to this work
Purpose: Statins, known as inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG CoA) reductases, are designed to treat lipid disorders, especially hypercholesterolemia. Apart from their role in preventing heart diseases in patients with high cholesterol, recent evidence suggests that statins have anti-tumor properties. However, studies assessing the association between statin use and esophageal cancer survival outcomes have provided controversial results.
Methods: We conducted a systematic review and meta-analysis focusing on studies evaluating associations between statin use and survival outcomes for esophageal cancer patients.
Results: A total of five cohort studies comprising 24,576 patients were included. Statin use associated with improved overall survival (OS: HR 0.84, 95% CI, 0.75–0.94) and disease-free survival (DFS: HR 0.84, 95% CI, 0.75–0.96) of esophageal cancer patients. The improved survival outcomes were consistent in the esophageal adenocarcinoma subgroup and the esophageal squamous cell cancer subgroup.
Conclusion: A potential therapeutic role of statins in esophageal cancer has been demonstrated in our study, however, the results should be interpreted cautiously and need further confirmation by future studies.
Keywords: statins, esophageal cancer, survival outcome, drug repositioning
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]